Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: The present disclosure relates to tissue supports for use with engineered tissues and organoids, such as cardiac organoid chambers. In an embodiment of the present disclosure, the tissue supports are provided with a fluid-impermeable resilient member that is resiliently deformable during testing by cultured tissues formed on the surface of the tissue support.

Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: A method of treating or preventing supraventricular tachyarrhythmias is disclosed which comprises the use of a compound which selectively blocks the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium.

Abstract: This application discloses a method of treating or preventing atrial arrhythmias which utilizes compounds which are blockers of the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium in a use-dependent and/or rate dependent manner, and which provide the selective block preferentially at fast heart rates so that the effect is realized or maximized when required.

Abstract: This application discloses a method of treating or preventing atrial arrhythmias which utilizes compounds which are blockers of the ultra-rapidly-activating delayed rectifier K.sup.+ current (I.sub.Kur) of the human atrium in a use-dependent and/or rate dependent manner, and which provide the selective block preferentially at fast heart rates so that the effect is realized or maximized when required.

Abstract: A method of treating or preventing supraventricular tachyarrhythmias is disclosed which comprises the use of a compound which selectively blocks the ultra-rapidly-activating delayed rectifier K.sup.+ current (I.sub.Kur) of the human atrium.